Discussion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [2]
Long-term administration of antiangiogenic agents does not directly indicate a high risk of MRONJ [16], though some authors have established 7-, 14-, and 28-day intervals of bevacizumab suspension for oral surgery [17,18,19]. In this case, the antiangiogenic medication was suspended for 28 days before implant placement; however, this was not enough to prevent MRONJ. The surfaces of Straumann® SLactive implants have been shown to present rapid osseointegration occurring between 21 and 28 days before implantation [20]. In order to avoid interference with the bevacizumab regimen and to accelerate osseointegration, Straumann® Bone Level Tapered-BLT® implants (SLactive) were used in this case. Of the four inserted implants, three were osseointegrated by the time that osteonecrosis manifested. Kwon et al., in 2014 [7], also reported bone sequestration involving histologically osseointegrated implants. On the other hand, the formation of sequestra may still continue in the deep regions of cancellous bone.
August et al. [21] reported in 2002 that the survival rate of dental implants is not significantly impacted by chemotherapy, regardless of whether administered before or after implant insertion. In contrast, Dantas et al. [22] reported that a 30-day period of chemotherapy suspension for implant placement would negatively affect osseointegration. Therefore, a consensus could not be established regarding the exact safe period for dental implant placement in patients undergoing chemotherapy. In this case, docetaxel and carboplatin infusions had been already suspended for 3 months preoperatively and resumed 3 months postoperatively. Additionally, these infusions do not represent a risk factor for MRONJ, according to Ruggiero et al. [9].
In addition to the risk of MRONJ for oral surgery, oral function and quality of life also play important roles in deciding the indications for a dental surgical procedure on a patient receiving antiresorptive agents [23]. To the best of our knowledge, no contraindication for dental implant installation in patients exposed to bevacizumab has been reported in scientific literature, when a period of 28 days without medication is observed pre-and post-procedure [17,18,19]. Nonetheless, specialists should be aware of the complexity of managing such patients.
Serial posts:
- Background : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Case presentation : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [1]
- Case presentation : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [2]
- Discussion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [1]
- Discussion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [2]
- Discussion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [3]
- Conclusions : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Availability of data and materials : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Abbreviations : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- References : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [1]
- References : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [2]
- References : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [3]
- Acknowledgements : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Funding : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Author information : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Ethics declarations : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Additional information : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Rights and permissions : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- About this article : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
- Fig. 1. Initial clinical image showing oral infection foci : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 2. a, b Tomographic findings: lesions, measurements, and bone quality : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 3. Panoramic radiograph after dental extractions with subsequent dental implants : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 4. Bone exposure surrounding the implants with drainage of purulent secretion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 5. a, b Histological image of the lesion : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 6. Image obtained 7 months postoperatively showing no lesions : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Fig. 7. Panoramic radiograph at 7-month follow-up : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implant
- Pendanaan : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Latar Belakang : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Presentasi kasus : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [1]
- Presentasi kasus : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [2]
- Discussion : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [1]
- Discussion : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [2]
- Kesimpulan : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Ketersediaan data dan bahan : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Abbreviations : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Referensi : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [1]
- Referensi : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [2]
- Referensi : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi [3]
- Ucapan Terima Kasih : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Informasi penulis : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Deklarasi etika : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Informasi tambahan : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Hak dan izin : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi
- Tentang artikel ini : Kasus langka osteonekrosis rahang terkait bevacizumab terkait dengan implan gigi